- Home
- HAYN vs ABUS Comparison
HAYN vs ABUS Comparison
Compare HAYN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYN
- ABUS
- Stock Information
- Founded
- HAYN 1912
- ABUS N/A
- Country
- HAYN United States
- ABUS United States
- Employees
- HAYN N/A
- ABUS N/A
- Industry
- HAYN Steel/Iron Ore
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- HAYN Industrials
- ABUS Health Care
- Exchange
- HAYN Nasdaq
- ABUS Nasdaq
- Market Cap
- HAYN 772.3M
- ABUS 725.9M
- IPO Year
- HAYN N/A
- ABUS N/A
- Fundamental
- Price
- HAYN $60.48
- ABUS $3.73
- Analyst Decision
- HAYN Hold
- ABUS Strong Buy
- Analyst Count
- HAYN 2
- ABUS 4
- Target Price
- HAYN N/A
- ABUS $5.38
- AVG Volume (30 Days)
- HAYN 178.4K
- ABUS 857.8K
- Earning Date
- HAYN 11-14-2024
- ABUS 11-06-2024
- Dividend Yield
- HAYN 1.45%
- ABUS N/A
- EPS Growth
- HAYN N/A
- ABUS N/A
- EPS
- HAYN 2.90
- ABUS N/A
- Revenue
- HAYN $614,334,000.00
- ABUS $6,742,000.00
- Revenue This Year
- HAYN $4.73
- ABUS N/A
- Revenue Next Year
- HAYN $3.41
- ABUS N/A
- P/E Ratio
- HAYN $20.88
- ABUS N/A
- Revenue Growth
- HAYN 7.18
- ABUS N/A
- 52 Week Low
- HAYN $45.87
- ABUS $1.70
- 52 Week High
- HAYN $60.86
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- HAYN 59.81
- ABUS 39.13
- Support Level
- HAYN $60.25
- ABUS $3.60
- Resistance Level
- HAYN $60.67
- ABUS $3.99
- Average True Range (ATR)
- HAYN 0.30
- ABUS 0.15
- MACD
- HAYN -0.01
- ABUS -0.02
- Stochastic Oscillator
- HAYN 63.54
- ABUS 23.64
About HAYN Haynes International Inc.
Haynes International Inc is a producer of high-performance nickel and cobalt-based alloys. The company is focused on developing, manufacturing, marketing, and distributing technology and high-performance alloys. The company operates in a single segment: the design, manufacture, marketing, and distribution of technologically advanced, high-performance alloys for use in the aerospace, industrial gas turbine, chemical processing, and other industries Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, China, and other countries.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.